Tumor lysing genetically engineered t cells loaded with multi-modal imaging agents

Parijat Bhatnagar, Mian Alauddin, James A. Bankson, Dickson Kirui, Payam Seifi, Helen Huls, Dean A. Lee, Aydin Babakhani, Mauro Ferrari, King C. Li, Laurence J N Cooper

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Genetically-modified T cells expressing chimeric antigen receptors (CAR) exert anti-tumor effect by identifying tumor-associated antigen (TAA), independent of major histocompatibility complex. For maximal efficacy and safety of adoptively transferred cells, imaging their biodistribution is critical. This will determine if cells home to the tumor and assist in moderating cell dose. Here, T cells are modified to express CAR. An efficient, non-toxic process with potential for cGMP compliance is developed for loading high cell number with multi-modal (PET-MRI) contrast agents (Super Paramagnetic Iron Oxide Nanoparticles - Copper-64; SPION- 64 Cu). This can now be potentially used for 64 Cu-based whole-body PET to detect T cell accumulation region with high-sensitivity, followed by SPION-based MRI of these regions for high-resolution anatomically correlated images of T cells. CD19-specific-CAR + SPION pos T cells effectively target in vitro CD19 + lymphoma.

Original languageEnglish (US)
Article number4502
JournalScientific Reports
StatePublished - Mar 28 2014

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Tumor lysing genetically engineered t cells loaded with multi-modal imaging agents'. Together they form a unique fingerprint.

Cite this